An interventional study of Spirometry and Accelerometry in Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, sponsored by Hoffmann-La Roche. Completed at 37 sites in 6 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-03-26.
Sponsored by Hoffmann-La Roche · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Idiopathic Pulmonary Fibrosis · Hoffmann-La Roche.
Among the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche, this one is the 11th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2017, is the only one with no phase, and was the 26th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →None of the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche is open now. The open studies under Idiopathic Pulmonary Fibrosis, anywhere →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 178 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 150 across the 24 interventional studies, 204 across the 4 observational. Of the 27 that completed or were terminated, 15 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,101 studies on the registry; 88 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Idiopathic Pulmonary Fibrosis by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This international clinical study will enroll participants with a suspected diagnosis of IPF/ILD. This study will characterize the disease behavior of IPF and ILD in the peri-diagnostic period. This objective will be achieved using a multidimensional approach assessing changes in pulmonary function, measured by daily handheld spirometry and site spirometry as well as assessing physical functional capacity at home (accelerometry) and at site (6-minute walk tests [6MWT]). Daily handheld spirometry or physical functional capacity assessments are not routinely performed in this participant population. By following participants' lung function before and after diagnosis using home spirometry, levels of physical activity, as well as self-assessment data from the participants (patient reported outcomes; PRO), the study would provide potentially more rapid information on disease behavior and eventually progression compared to usual clinic measurements that occur only every 3-6 months. By receiving data from daily handheld spirometry measurements, treating physicians may have an improved chance of detecting earlier and outside of hospital visits a decline in lung function that could potentially lead to improvements in both diagnosis and treatment for participants with IPF/ILD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A participant will be eligible for inclusion if the Investigator has a suspicion that the participant may have IPF/ILD based on symptoms and radiological evidence.
Other: Spirometry · Other: Accelerometry · Other: 6MWT
Daily spirometry will be conducted by the participant at home using the study kit provided. Spirometry assessments (FVC) will be conducted at approximately the same time each day with the participant in a seated position. Additionally, site spirometry will also be performed during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
Daily physical functional capacity assessments (e.g., steps per day, calorie expenditure) will be measured on an ongoing basis using the accelerometry device provided.
The 6MWT will be performed only at sites where a formalized process is available and the test can be performed under safe conditions, during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
Time-Adjusted Semi-Annual Forced Vital Capacity (FVC) Decline in Participants With IPF During the Peri-Diagnostic Period, Measured in Milliliters (mL) by Daily Home Spirometry
Minimum site visits were: baseline, diagnosis, and EOS for each participant. From inclusion into the study, participants were followed for up to12 months. The EOS was defined as: If no diagnosis was made 12 months after inclusion, the participant left the study; Participants diagnosed with non-ILD left the study on the date of diagnosis; Participants diagnosed with IPF or non-IPF ILD were followed up to the start of drug treatment (within 6 months) or up to 6 months if no drug treatment was prescribed. Therefore, the total length of the study was variable for each participant. Measurements were taken daily by home spirometry. The semi-annual mean FVC decline was calculated by use of the estimated semi-annual FVC decline of each individual participant. The individual FVC decline was estimated by applying a linear regression model to all acceptable FVC measurements flagged as 'Good blow' collected by the individual participant during the entire peri-diagnostic period (up to 18 months).
Time frame: From Day 1 into the study to end of the study (up to 18 months) and adjusted for 6 months. There was no fixed visit schedule for the whole study and reported results comprise all data points from enrollment to EOS
Time-Adjusted Semi-Annual FVC Decline in Participants With Non-IPF ILD During the Peri-Diagnostic Period, Measured in mL by Daily Home Spirometry
Minimum site visits were: baseline, diagnosis, and EOS for each participant. From inclusion into the study, participants were followed for up to12 months. The EOS was defined as: If no diagnosis was made 12 months after inclusion, the participant left the study; Participants diagnosed with non-ILD left the study on the date of diagnosis; Participants diagnosed with IPF or non-IPF ILD were followed up to the start of drug treatment (within 6 months) or up to 6 months if no drug treatment was prescribed. Therefore, the total length of the study was variable for each participant. Measurements were taken daily by home spirometry. The semi-annual mean FVC decline was calculated by use of the estimated semi-annual FVC decline of each individual participant. The individual FVC decline was estimated by applying a linear regression model to all acceptable FVC measurements flagged as 'Good blow' collected by the individual participant during the entire peri-diagnostic period (up to 18 months).
Time frame: From Day 1 into the study to end of the study (up to 18 months) and adjusted for 6 months. There was no fixed visit schedule for the whole study and reported results comprise all data points from enrollment to EOS
Change From Baseline in the FVC Decline in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured in mL by Site Spirometry
The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Time frame: From Baseline to end of the study (up to 18 months)
Change From Baseline in the Percent Predicted FVC in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Site Spirometry
The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Time frame: From Baseline to end of the study (up to 18 months)
Change From Baseline in Distance Walked (Meters) on the 6MWT in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Assessed at Site
The 6MWT measures the distance a patient is able to walk quickly on a flat, hard surface in a period of 6 minutes. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Time frame: From Baseline to end of the study (up to 18 months)
Decline in Physical Function Capacity (Steps/Day) in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry
Patients were asked to wear an accelerometer during the course of the study which provided information on their physical activity at home, with daily measurements used to investigate the development of physical function capacity. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Time frame: From inclusion into the study to end of the study (up to 18 months)
Calorie Expenditure in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry
Time frame: From inclusion into the study to end of the study (up to 18 months)
Change in the King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score by Visit During the Peri-Diagnostic Period
The K-BILD questionnaire was specifically developed to analyze the health status of participants with ILD. The questionnaire consists of 15 items (assessed by the patients on a scale ranging from 1 to 7, where 1 and 7 represent worst and best health status). Items are compiled into 3 domains: breathlessness and activities (range: 0-21), psychological (range: 0-34) , and chest symptoms (range: 0-8). To score the K-BILD, the Likert response scale weightings for individual items are combined and scores are transformed to a range of 0-100 by using logit values (higher scores indicate better health status). The peri-diagnostic period covered the pre-diagnostic period (from enrollment visit participants were followed for up to 12 months) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Time frame: From inclusion into the study to end of the study (up to 18 months)
Modified Medical Research Council (mMRC) Dyspnea Scale Scores During the Peri-Diagnostic Period
The mMRC dyspnea scale was used to grade the effects of breathlessness on daily activities over time. The following grading categories are used for this scale: Grade 0 - I only get breathless with strenuous exercise; Grade 1 - I get short of breath when hurrying on the level or walking up a slight hill; Grade 2 - I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking on my own pace; Grade 3 - I stop for breath after walking about 100 yards or after a few minutes on level ground; Grade 4 - I am too breathless to leave the house. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Time frame: From inclusion into the study to end of the study (up to 18 months)
The EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) 5-Item Health State Profile Scores During the Peri-Diagnostic Period
The EQ-5D-5L questionnaire is a self-reported health status questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item is rated by the participant on a five-point scale indicating the followings: Level 1 - no problem; Level 2 - slight problems; Level 3 - moderate problems; Level 4 - severe problems; Level 5 - extreme problems. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Time frame: From inclusion into the study to end of the study (up to 18 months)
The EuroQol Visual Analogue Scale (EQ-VAS) Health State Profile Scores During the Peri-Diagnostic Period During the Peri-Diagnostic Period
The EQ-VAS questionnaire is a self-reported questionnaire that measures health state. The VAS is a 100 mm scale from worst (0 mm) to best (100 mm) health the participant can imagine. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Time frame: From inclusion into the study to end of the study (up to 18 months)
The EuroQoL 5-dimension 5-level Questionnaire Index Utility Scores During the Peri-Diagnostic Period
The EQ-5D-5L questionnaire is a self-reported health status questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A unique health state is defined for each participant by combining the levels from each of the 5 dimensions. Each state is referred to in terms of a 5 digit code, e.g. state 11111 indicates no problems on any of the 5 dimensions, while state 12345 indicates no problems with mobility, slight problems with washing or dressing, moderate problems with usual activities, severe pain or discomfort and extreme anxiety or depression. From these 5 answers an index value is derived between 0 and 1, with a higher value corresponding with a better Quality of Life.
Time frame: From inclusion into the study to end of the study (up to 18 months)
Fatigue Assessment Scale (FAS) Score During the Peri-Diagnostic Period
The FAS is a fatigue questionnaire consisting of 10 items; five questions reflect physical fatigue and five questions analyze mental fatigue. A five-point scale (one for "never" to five for "always") is used for participant responses. The scale score is calculated by summing all items. Therefore, the FAS scores can range from 10 to 50. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Time frame: From inclusion into the study to end of the study (up to 18 months)
Cough, Urge to Cough, and Fatigue Visual Analogue Scales (VAS) Score During the Peri-Diagnostic Period
The VAS are 100 mm scales on which participants indicate the severity of their cough, the urge to cough and their fatigue. In the VAS, participants had to record their health state on a scale ranging from 0 (best imaginable health state) to 100 (worst imaginable health state). A mean of this health state was recorded for participant analyzed in this outcome measure. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Time frame: From inclusion into the study to end of the study (up to 18 months)
Pearson's Correlation Coefficient of FVC (mL) Between Home and Site Spirometry in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period
The correlation of FVC (mL) between home and site spirometry was analyzed by taking into account the individually estimated linear regression models of each participant for home-based FVC measurements and site FVC measurements. This analysis was performed for participants diagnosed with IPF or non-IPF ILD in the peri-diagnosis period. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Time frame: From inclusion into the study to end of the study (up to 18 months)
Pearson's Correlation Coefficient of Physical Functional Capacity Assessed at Home in Terms of the Decline in the Number of Footsteps and on Site in Terms of the Decline in Distance of the 6MWT
The measure represents the correlation of distance walked (meter) assessed by physical function capacity at home and the 6MWT at the site in the peri-diagnosis period. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
Time frame: From inclusion into the study to end of the study (up to 18 months)
Percentage of Participants Requiring Respiratory-Related Hospitalizations
The number of participants requiring the hospitalization were counted during pre- and post-diagnosis period.
Time frame: From inclusion into the study to end of the study (up to 18 months)
Percentage of Participants With Non-Elective Hospitalizations
The number of participants requiring the hospitalization were counted during pre- and post-diagnosis period. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.
Time frame: From inclusion into the study to end of the study (up to 18 months)
Percentage of Participants With Investigator-Reported Acute Exacerbations
Acute exacerbation was defined as per Collard et al. 2016. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.
Time frame: From inclusion into the study to end of the study (up to 18 months)
Percentage of Participants Who Died Due to Any Cause
The number of participants, who died due to any cause, were counted during pre- and post-diagnosis period.
Time frame: From inclusion into the study to end of the study (up to 18 months)
Percentage of Participants Who Died Due to Respiratory-Related Diseases
The number of participants, who died due to respiratory-related diseases, were counted during pre- and post-diagnosis period.
Time frame: From inclusion into the study to end of the study (up to 18 months)
Percentage of Participants With Events Related to the Study Assessments
The number of participants with events related to the study assessments were counted during pre- and post-diagnosis period. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.
Time frame: From inclusion into the study to end of the study (up to 18 months)
The study enrolled participants in Canada, France, Ireland, Italy, the Netherlands, and Russia.
| Milestone | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis |
|---|---|---|---|---|
| Started | 68 | 62 | 9 | 39 |
| Completed | 64 | 41 | 9 | 11 |
| Not completed | 4 | 21 | 0 | 28 |
| Withdrew: Withdrawal by subject | 2 | 13 | 0 | 18 |
| Withdrew: Non-compliance with study procedures | 0 | 2 | 0 | 6 |
| Withdrew: Participant moving away and can no longer be in study | 0 | 1 | 0 | 0 |
| Withdrew: Participant came out of study due to investigator discretion | 0 | 2 | 0 | 0 |
| Withdrew: Diagnosed but protocol deviation | 1 | 0 | 0 | 0 |
| Withdrew: Participant did not want to continue the study | 0 | 1 | 0 | 0 |
| Withdrew: Participant did not want to continue the diagnostic procedures | 0 | 0 | 0 | 1 |
| Withdrew: Participant presented clinical improvement | 0 | 2 | 0 | 0 |
| Withdrew: Technical difficulties | 0 | 0 | 0 | 1 |
| Withdrew: Equipment failed to work | 0 | 0 | 0 | 1 |
| Withdrew: End of study for participant and no follow up | 0 | 0 | 0 | 1 |
| Withdrew: Participant was too weak to continue in study | 1 | 0 | 0 | 0 |
Minimum site visits were: baseline, diagnosis, and EOS for each participant. From inclusion into the study, participants were followed for up to12 months. The EOS was defined as: If no diagnosis was made 12 months after inclusion, the participant left the study; Participants diagnosed with non-ILD left the study on the date of diagnosis; Participants diagnosed with IPF or non-IPF ILD were followed up to the start of drug treatment (within 6 months) or up to 6 months if no drug treatment was prescribed. Therefore, the total length of the study was variable for each participant. Measurements were taken daily by home spirometry. The semi-annual mean FVC decline was calculated by use of the estimated semi-annual FVC decline of each individual participant. The individual FVC decline was estimated by applying a linear regression model to all acceptable FVC measurements flagged as 'Good blow' collected by the individual participant during the entire peri-diagnostic period (up to 18 months).
| milliliter (mL) | IPF Participants |
|---|---|
| Time-Adjusted Semi-Annual Forced Vital Capacity (FVC) Decline in Participants With IPF During the Peri-Diagnostic Period, Measured in Milliliters (mL) by Daily Home Spirometry | -308.7 ± 1268.72 |
Minimum site visits were: baseline, diagnosis, and EOS for each participant. From inclusion into the study, participants were followed for up to12 months. The EOS was defined as: If no diagnosis was made 12 months after inclusion, the participant left the study; Participants diagnosed with non-ILD left the study on the date of diagnosis; Participants diagnosed with IPF or non-IPF ILD were followed up to the start of drug treatment (within 6 months) or up to 6 months if no drug treatment was prescribed. Therefore, the total length of the study was variable for each participant. Measurements were taken daily by home spirometry. The semi-annual mean FVC decline was calculated by use of the estimated semi-annual FVC decline of each individual participant. The individual FVC decline was estimated by applying a linear regression model to all acceptable FVC measurements flagged as 'Good blow' collected by the individual participant during the entire peri-diagnostic period (up to 18 months).
| mL | Non-IPF ILD Participants |
|---|---|
| Time-Adjusted Semi-Annual FVC Decline in Participants With Non-IPF ILD During the Peri-Diagnostic Period, Measured in mL by Daily Home Spirometry | 57.5 ± 1277.03 |
The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
| mL | IPF Participants | Non-IPF ILD Participants |
|---|---|---|
| Baseline | 2845.6 ± 814.83 | 2782.4 ± 870.24 |
| Change from Baseline at End of Study Visit | -51.3 ± 270.56 | -27.1 ± 265.52 |
The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
| Percent Predicted (%) | IPF Participants | Non-IPF ILD Participants |
|---|---|---|
| Baseline | 82.8 ± 18.74 | 83.9 ± 17.82 |
| Change form Baseline at End of Study Visit | -0.6 ± 7.26 | -0.6 ± 8.49 |
The 6MWT measures the distance a patient is able to walk quickly on a flat, hard surface in a period of 6 minutes. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
| Meter (m) | IPF Participants | Non-IPF ILD Participants |
|---|---|---|
| Baseline | 434.6 ± 117.30 | 429.4 ± 139.51 |
| Change from Baseline at End of Study Visit | 4.4 ± 96.18 | 6.4 ± 87.97 |
Patients were asked to wear an accelerometer during the course of the study which provided information on their physical activity at home, with daily measurements used to investigate the development of physical function capacity. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
| Steps per Day | IPF Participants | Non-IPF ILD Participants |
|---|---|---|
| Decline in Physical Function Capacity (Steps/Day) in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry | -1237.2 ± 14146.07 | -13407.3 ± 72612.82 |
| Calorie | IPF Participants | Non-IPF ILD Participants |
|---|---|---|
| Calorie Expenditure in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period, Measured by Daily Home Accelerometry | NA | NA |
The K-BILD questionnaire was specifically developed to analyze the health status of participants with ILD. The questionnaire consists of 15 items (assessed by the patients on a scale ranging from 1 to 7, where 1 and 7 represent worst and best health status). Items are compiled into 3 domains: breathlessness and activities (range: 0-21), psychological (range: 0-34) , and chest symptoms (range: 0-8). To score the K-BILD, the Likert response scale weightings for individual items are combined and scores are transformed to a range of 0-100 by using logit values (higher scores indicate better health status). The peri-diagnostic period covered the pre-diagnostic period (from enrollment visit participants were followed for up to 12 months) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
| Units on scale | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis |
|---|---|---|---|---|
| Baseline | 60.57 ± 17.633 | 55.70 ± 14.203 | 54.22 ± 11.703 | 60.47 ± 15.728 |
| Change from Baseline at End of Study Visit | -0.45 ± 9.709 | 3.98 ± 11.851 | 6.03 ± 14.294 | 4.01 ± 9.313 |
The mMRC dyspnea scale was used to grade the effects of breathlessness on daily activities over time. The following grading categories are used for this scale: Grade 0 - I only get breathless with strenuous exercise; Grade 1 - I get short of breath when hurrying on the level or walking up a slight hill; Grade 2 - I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking on my own pace; Grade 3 - I stop for breath after walking about 100 yards or after a few minutes on level ground; Grade 4 - I am too breathless to leave the house. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
| Participants | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis |
|---|---|---|---|---|
| Pre-diagnosis — Grade 0 | 12 | 10 | 2 | 6 |
| Pre-diagnosis — Grade 1 | 8 | 8 | 1 | 11 |
| Pre-diagnosis — Grade 2 | 7 | 9 | 3 | 2 |
| Pre-diagnosis — Grade 3 | 3 | 2 | 1 | 1 |
| Pre-diagnosis — Grade 4 | 0 | 0 | 0 | 0 |
| Initial diagnosis — Grade 0 | 22 | 17 | 3 | 2 |
| Initial diagnosis — Grade 1 | 31 | 25 | 0 | 0 |
| Initial diagnosis — Grade 2 | 10 | 16 | 3 | 1 |
| Initial diagnosis — Grade 3 | 5 | 3 | 2 | 0 |
| Initial diagnosis — Grade 4 | 0 | 0 | 0 | 0 |
| Post-diagnosis — Grade 0 | 2 | 1 | — | — |
| Post-diagnosis — Grade 1 | 4 | 2 | — | — |
| Post-diagnosis — Grade 2 | 0 | 0 | — | — |
| Post-diagnosis — Grade 3 | 0 | 0 | — | — |
| Post-diagnosis — Grade 4 | 0 | 0 | — | — |
| End of Study — Grade 0 | 20 | 17 | 3 | 13 |
| End of Study — Grade 1 | 30 | 25 | 1 | 15 |
| End of Study — Grade 2 | 10 | 16 | 3 | 3 |
| End of Study — Grade 3 | 5 | 3 | 2 | 1 |
| End of Study — Grade 4 | 0 | 0 | 0 | 0 |
The EQ-5D-5L questionnaire is a self-reported health status questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item is rated by the participant on a five-point scale indicating the followings: Level 1 - no problem; Level 2 - slight problems; Level 3 - moderate problems; Level 4 - severe problems; Level 5 - extreme problems. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
| Participants | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis |
|---|---|---|---|---|
| Baseline Mobility — Level 1 | 33 | 25 | 2 | 24 |
| Baseline Mobility — Level 2 | 16 | 15 | 2 | 9 |
| Baseline Mobility — Level 3 | 14 | 21 | 5 | 4 |
| Baseline Mobility — Level 4 | 5 | 1 | 0 | 1 |
| Baseline Mobility — Level 5 | 0 | 0 | 0 | 0 |
| Baseline Mobility — Missing | 0 | 0 | 0 | 0 |
| Baseline Self-care — Level 1 | 55 | 52 | 6 | 34 |
| Baseline Self-care — Level 2 | 7 | 6 | 2 | 4 |
| Baseline Self-care — Level 3 | 6 | 4 | 1 | 0 |
| Baseline Self-care — Level 4 | 0 | 0 | 0 | 0 |
| Baseline Self-care — Level 5 | 0 | 0 | 0 | 0 |
| Baseline Self-care — Missing | 0 | 0 | 0 | 0 |
| Baseline Usual activities — Level 1 | 32 | 29 | 4 | 20 |
| Baseline Usual activities — Level 2 | 19 | 16 | 2 | 10 |
| Baseline Usual activities — Level 3 | 16 | 15 | 2 | 4 |
| Baseline Usual activities — Level 4 | 1 | 2 | 0 | 4 |
| Baseline Usual activities — Level 5 | 0 | 0 | 1 | 0 |
| Baseline Usual activities — Missing | 0 | 0 | 0 | 0 |
| Baseline Pain/Discomfort — Level 1 | 29 | 25 | 3 | 20 |
| Baseline Pain/Discomfort — Level 2 | 22 | 22 | 2 | 10 |
| Baseline Pain/Discomfort — Level 3 | 17 | 14 | 3 | 4 |
| Baseline Pain/Discomfort — Level 4 | 0 | 1 | 1 | 3 |
| Baseline Pain/Discomfort — Level 5 | 0 | 0 | 0 | 1 |
| Baseline Pain/Discomfort — Missing | 0 | 0 | 0 | 0 |
| Baseline Anxiety/Depression — Level 1 | 38 | 24 | 5 | 19 |
| Baseline Anxiety/Depression — Level 2 | 22 | 20 | 2 | 12 |
| Baseline Anxiety/Depression — Level 3 | 5 | 15 | 2 | 7 |
| Baseline Anxiety/Depression — Level 4 | 2 | 2 | 0 | 0 |
| Baseline Anxiety/Depression — Level 5 | 1 | 1 | 0 | 0 |
| Baseline Anxiety/Depression — Missing | 0 | 0 | 0 | 0 |
| Pre-diagnosis Mobility — Level 1 | 16 | 11 | 1 | 13 |
| Pre-diagnosis Mobility — Level 2 | 4 | 9 | 2 | 4 |
| Pre-diagnosis Mobility — Level 3 | 9 | 5 | 2 | 1 |
| Pre-diagnosis Mobility — Level 4 | 1 | 3 | 2 | 2 |
| Pre-diagnosis Mobility — Level 5 | 0 | 0 | 0 | 0 |
| Pre-diagnosis Mobility — Missing | 0 | 1 | 0 | 1 |
| Pre-diagnosis Self-care — Level 1 | 25 | 25 | 5 | 20 |
| Pre-diagnosis Self-care — Level 2 | 3 | 2 | 2 | 0 |
| Pre-diagnosis Self-care — Level 3 | 1 | 1 | 0 | 0 |
| Pre-diagnosis Self-care — Level 4 | 1 | 0 | 0 | 0 |
| Pre-diagnosis Self-care — Level 5 | 0 | 0 | 0 | 0 |
| Pre-diagnosis Self-care — Missing | 0 | 1 | 0 | 1 |
| Pre-diagnosis Usual activities — Level 1 | 15 | 15 | 2 | 9 |
| Pre-diagnosis Usual activities — Level 2 | 10 | 6 | 3 | 6 |
| Pre-diagnosis Usual activities — Level 3 | 4 | 7 | 2 | 4 |
| Pre-diagnosis Usual activities — Level 4 | 1 | 0 | 0 | 0 |
| Pre-diagnosis Usual activities — Level 5 | 0 | 0 | 0 | 1 |
| Pre-diagnosis Usual activities — Missing | 0 | 1 | 0 | 1 |
| Pre-diagnosis Pain/Discomfort — Level 1 | 15 | 15 | 1 | 12 |
| Pre-diagnosis Pain/Discomfort — Level 2 | 11 | 7 | 4 | 3 |
| Pre-diagnosis Pain/Discomfort — Level 3 | 3 | 5 | 0 | 4 |
| Pre-diagnosis Pain/Discomfort — Level 4 | 1 | 1 | 2 | 0 |
| Pre-diagnosis Pain/Discomfort — Level 5 | 0 | 0 | 0 | 1 |
| Pre-diagnosis Pain/Discomfort — Missing | 0 | 1 | 0 | 1 |
| Pre-diagnosis Anxiety/Depression — Level 1 | 14 | 12 | 2 | 10 |
| Pre-diagnosis Anxiety/Depression — Level 2 | 11 | 10 | 4 | 8 |
| Pre-diagnosis Anxiety/Depression — Level 3 | 3 | 6 | 1 | 1 |
| Pre-diagnosis Anxiety/Depression — Level 4 | 0 | 0 | 0 | 0 |
| Pre-diagnosis Anxiety/Depression — Level 5 | 2 | 0 | 0 | 1 |
| Pre-diagnosis Anxiety/Depression — Missing | 0 | 1 | 0 | 1 |
| Initial diagnosis Mobility — Level 1 | 31 | 26 | 2 | 2 |
| Initial diagnosis Mobility — Level 2 | 19 | 17 | 3 | 0 |
| Initial diagnosis Mobility — Level 3 | 12 | 9 | 2 | 0 |
| Initial diagnosis Mobility — Level 4 | 3 | 6 | 1 | 0 |
| Initial diagnosis Mobility — Level 5 | 0 | 0 | 0 | 0 |
| Initial diagnosis Mobility — Missing | 3 | 4 | 0 | 1 |
| Initial diagnosis Self-care — Level 1 | 55 | 44 | 6 | 2 |
| Initial diagnosis Self-care — Level 2 | 3 | 10 | 1 | 0 |
| Initial diagnosis Self-care — Level 3 | 6 | 4 | 1 | 0 |
| Initial diagnosis Self-care — Level 4 | 1 | 0 | 0 | 0 |
| Initial diagnosis Self-care — Level 5 | 0 | 0 | 0 | 0 |
| Initial diagnosis Self-care — Missing | 3 | 4 | 0 | 1 |
| Initial diagnosis Usual activities — Level 1 | 31 | 27 | 6 | 2 |
| Initial diagnosis Usual activities — Level 2 | 20 | 14 | 1 | 0 |
| Initial diagnosis Usual activities — Level 3 | 9 | 14 | 1 | 0 |
| Initial diagnosis Usual activities — Level 4 | 4 | 3 | 0 | 0 |
| Initial diagnosis Usual activities — Level 5 | 1 | 0 | 0 | 0 |
| Initial diagnosis Usual activities — Missing | 3 | 4 | 0 | 1 |
| Initial diagnosis Pain/Discomfort — Level 1 | 32 | 34 | 2 | 1 |
| Initial diagnosis Pain/Discomfort — Level 2 | 22 | 14 | 1 | 1 |
| Initial diagnosis Pain/Discomfort — Level 3 | 10 | 6 | 3 | 0 |
| Initial diagnosis Pain/Discomfort — Level 4 | 1 | 4 | 2 | 0 |
| Initial diagnosis Pain/Discomfort — Level 5 | 0 | 0 | 0 | 0 |
| Initial diagnosis Pain/Discomfort — Missing | 3 | 4 | 0 | 1 |
| Initial diagnosis Anxiety/Depression — Level 1 | 30 | 25 | 4 | 1 |
| Initial diagnosis Anxiety/Depression — Level 2 | 21 | 17 | 1 | 1 |
| Initial diagnosis Anxiety/Depression — Level 3 | 10 | 13 | 1 | 0 |
| Initial diagnosis Anxiety/Depression — Level 4 | 2 | 3 | 2 | 0 |
| Initial diagnosis Anxiety/Depression — Level 5 | 2 | 0 | 0 | 0 |
| Initial diagnosis Anxiety/Depression — Missing | 3 | 4 | 0 | 1 |
| Post-diagnosis Mobility — Level 1 | 2 | 0 | — | — |
| Post-diagnosis Mobility — Level 2 | 1 | 2 | — | — |
| Post-diagnosis Mobility — Level 3 | 2 | 1 | — | — |
| Post-diagnosis Mobility — Level 4 | 0 | 0 | — | — |
| Post-diagnosis Mobility — Level 5 | 0 | 0 | — | — |
| Post-diagnosis Mobility — Missing | 1 | 0 | — | — |
| Post-diagnosis Self-care — Level 1 | 4 | 2 | — | — |
| Post-diagnosis Self-care — Level 2 | 0 | 1 | — | — |
| Post-diagnosis Self-care — Level 3 | 1 | 0 | — | — |
| Post-diagnosis Self-care — Level 4 | 0 | 0 | — | — |
| Post-diagnosis Self-care — Level 5 | 0 | 0 | — | — |
| Post-diagnosis Self-care — Missing | 1 | 0 | — | — |
| Post-diagnosis Usual activities — Level 1 | 2 | 2 | — | — |
| Post-diagnosis Usual activities — Level 2 | 2 | 0 | — | — |
| Post-diagnosis Usual activities — Level 3 | 1 | 1 | — | — |
| Post-diagnosis Usual activities — Level 4 | 0 | 0 | — | — |
| Post-diagnosis Usual activities — Level 5 | 0 | 0 | — | — |
| Post-diagnosis Usual activities — Missing | 1 | 0 | — | — |
| Post-diagnosis Pain/Discomfort — Level 1 | 1 | 2 | — | — |
| Post-diagnosis Pain/Discomfort — Level 2 | 4 | 0 | — | — |
| Post-diagnosis Pain/Discomfort — Level 3 | 0 | 1 | — | — |
| Post-diagnosis Pain/Discomfort — Level 4 | 0 | 0 | — | — |
| Post-diagnosis Pain/Discomfort — Level 5 | 0 | 0 | — | — |
| Post-diagnosis Pain/Discomfort — Missing | 1 | 0 | — | — |
| Post-diagnosis Anxiety/Depression — Level 1 | 3 | 0 | — | — |
| Post-diagnosis Anxiety/Depression — Level 2 | 1 | 2 | — | — |
| Post-diagnosis Anxiety/Depression — Level 3 | 1 | 1 | — | — |
| Post-diagnosis Anxiety/Depression — Level 4 | 0 | 0 | — | — |
| Post-diagnosis Anxiety/Depression — Level 5 | 0 | 0 | — | — |
| Post-diagnosis Anxiety/Depression — Missing | 1 | 0 | — | — |
| End of Study Mobility — Level 1 | 33 | 28 | 2 | 16 |
| End of Study Mobility — Level 2 | 15 | 15 | 3 | 2 |
| End of Study Mobility — Level 3 | 11 | 14 | 3 | 4 |
| End of Study Mobility — Level 4 | 4 | 3 | 1 | 2 |
| End of Study Mobility — Level 5 | 0 | 0 | 0 | 0 |
| End of Study Mobility — Missing | 2 | 2 | 0 | 9 |
| End of Study Self-care — Level 1 | 54 | 46 | 6 | 22 |
| End of Study Self-care — Level 2 | 3 | 12 | 2 | 1 |
| End of Study Self-care — Level 3 | 5 | 2 | 1 | 1 |
| End of Study Self-care — Level 4 | 1 | 0 | 0 | 0 |
| End of Study Self-care — Level 5 | 0 | 0 | 0 | 0 |
| End of Study Self-care — Missing | 2 | 2 | 0 | 9 |
| End of Study Usual activities — Level 1 | 32 | 25 | 4 | 14 |
| End of Study Usual activities — Level 2 | 16 | 18 | 0 | 5 |
| End of Study Usual activities — Level 3 | 11 | 15 | 4 | 4 |
| End of Study Usual activities — Level 4 | 3 | 2 | 1 | 1 |
| End of Study Usual activities — Level 5 | 1 | 0 | 0 | 0 |
| End of Study Usual activities — Missing | 2 | 2 | 0 | 9 |
| End of Study Pain/Discomfort — Level 1 | 30 | 34 | 2 | 14 |
| End of Study Pain/Discomfort — Level 2 | 20 | 16 | 1 | 3 |
| End of Study Pain/Discomfort — Level 3 | 13 | 8 | 4 | 6 |
| End of Study Pain/Discomfort — Level 4 | 0 | 2 | 2 | 1 |
| End of Study Pain/Discomfort — Level 5 | 0 | 0 | 0 | 0 |
| End of Study Pain/Discomfort — Missing | 2 | 2 | 0 | 9 |
| End of Study Anxiety/Depression — Level 1 | 28 | 25 | 4 | 13 |
| End of Study Anxiety/Depression — Level 2 | 21 | 19 | 1 | 10 |
| End of Study Anxiety/Depression — Level 3 | 10 | 15 | 2 | 0 |
| End of Study Anxiety/Depression — Level 4 | 2 | 1 | 2 | 1 |
| End of Study Anxiety/Depression — Level 5 | 2 | 0 | 0 | 0 |
| End of Study Anxiety/Depression — Missing | 2 | 2 | 0 | 9 |
The EQ-VAS questionnaire is a self-reported questionnaire that measures health state. The VAS is a 100 mm scale from worst (0 mm) to best (100 mm) health the participant can imagine. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
| Scores on a scale | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis |
|---|---|---|---|---|
| Health State Index Baseline | 71.7 ± 15.96 | 67.4 ± 20.11 | 68.9 ± 17.99 | 76.2 ± 17.09 |
| Health State Index Pre-diagnosis | 69.8 ± 15.50 | 71.5 ± 15.89 | 65.7 ± 19.88 | 73.5 ± 16.06 |
| Health State Index Initial diagnosis | 69.5 ± 16.23 | 68.3 ± 18.03 | 70.4 ± 19.92 | 72.5 ± 10.61 |
| Health State Index Post-diagnosis | 69.0 ± 25.10 | 76.7 ± 12.58 | — | — |
| Health State Index End of Study | 69.5 ± 16.46 | 69.8 ± 17.21 | 67.0 ± 21.21 | 74.2 ± 16.85 |
The EQ-5D-5L questionnaire is a self-reported health status questionnaire that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A unique health state is defined for each participant by combining the levels from each of the 5 dimensions. Each state is referred to in terms of a 5 digit code, e.g. state 11111 indicates no problems on any of the 5 dimensions, while state 12345 indicates no problems with mobility, slight problems with washing or dressing, moderate problems with usual activities, severe pain or discomfort and extreme anxiety or depression. From these 5 answers an index value is derived between 0 and 1, with a higher value corresponding with a better Quality of Life.
| Scores on a scale | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis |
|---|---|---|---|---|
| Index utility score Baseline | 0.83 ± 0.140 | 0.79 ± 0.143 | 0.67 ± 0.250 | 0.80 ± 0.187 |
| Index utility score Pre-diagnosis | 0.82 ± 0.154 | 0.80 ± 0.152 | 0.68 ± 0.237 | 0.83 ± 0.182 |
| Index utility score Initial diagnosis | 0.81 ± 0.162 | 0.78 ± 0.197 | 0.63 ± 0.331 | 0.92 ± 0.013 |
| Index utility score Post-diagnosis | 0.81 ± 0.149 | 0.75 ± 0.123 | — | — |
| Index utility score End of Study | 0.81 ± 0.164 | 0.80 ± 0.164 | 0.62 ± 0.312 | 0.81 ± 0.197 |
The FAS is a fatigue questionnaire consisting of 10 items; five questions reflect physical fatigue and five questions analyze mental fatigue. A five-point scale (one for "never" to five for "always") is used for participant responses. The scale score is calculated by summing all items. Therefore, the FAS scores can range from 10 to 50. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
| Scores on a Scale | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis |
|---|---|---|---|---|
| Baseline | 21.8 ± 6.44 | 21.8 ± 6.89 | 21.1 ± 7.22 | 20.9 ± 6.99 |
| Initial diagnosis | 21.7 ± 6.66 | 22.6 ± 7.33 | 24.7 ± 9.11 | 18.0 ± 2.83 |
| End of study | 22.0 ± 6.17 | 22.0 ± 7.59 | 26.1 ± 9.33 | 20.6 ± 6.31 |
The VAS are 100 mm scales on which participants indicate the severity of their cough, the urge to cough and their fatigue. In the VAS, participants had to record their health state on a scale ranging from 0 (best imaginable health state) to 100 (worst imaginable health state). A mean of this health state was recorded for participant analyzed in this outcome measure. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
| Scores on a Scale | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis |
|---|---|---|---|---|
| Baseline (Cough) | 34.0 ± 25.44 | 26.9 ± 20.66 | 17.9 ± 21.99 | 27.4 ± 20.38 |
| Pre-diagnosis (Cough) | 36.8 ± 25.50 | 25.4 ± 20.90 | 11.4 ± 14.03 | 31.4 ± 24.34 |
| Initial diagnosis (Cough) | 36.3 ± 29.60 | 21.9 ± 18.88 | 17.1 ± 21.69 | 32.0 ± 36.77 |
| Post-diagnosis (Cough) | 25.6 ± 20.94 | 17.0 ± 9.16 | — | — |
| End of Study (Cough) | 34.7 ± 26.64 | 24.0 ± 19.42 | 19.3 ± 21.35 | 31.2 ± 25.92 |
| Baseline (Urge to Cough) | 33.3 ± 25.41 | 28.6 ± 21.53 | 16.4 ± 17.20 | 25.8 ± 21.27 |
| Pre-diagnosis (Urge to Cough) | 37.6 ± 25.73 | 23.1 ± 20.03 | 13.2 ± 13.51 | 30.4 ± 24.29 |
| Initial diagnosis (Urge to Cough) | 36.4 ± 29.22 | 22.9 ± 19.02 | 13.7 ± 19.86 | 38.5 ± 47.38 |
| Post-diagnosis (Urge to Cough) | 23.5 ± 15.79 | 10.8 ± 9.00 | — | — |
| End of Study (Urge to Cough) | 33.8 ± 25.18 | 24.3 ± 20.14 | 16.2 ± 20.00 | 36.3 ± 29.75 |
| Baseline (Fatigue) | 38.4 ± 27.15 | 39.4 ± 24.29 | 30.0 ± 31.18 | 33.2 ± 26.89 |
| Pre-diagnosis (Fatigue) | 34.1 ± 27.50 | 31.0 ± 22.68 | 32.5 ± 26.11 | 32.0 ± 28.29 |
| Initial diagnosis (Fatigue) | 37.5 ± 27.50 | 35.6 ± 23.79 | 31.1 ± 30.00 | 17.0 ± 5.66 |
| Post-diagnosis (Fatigue) | 30.4 ± 23.24 | 25.3 ± 19.48 | — | — |
| End of Study (Fatigue) | 38.3 ± 26.15 | 34.6 ± 23.54 | 35.5 ± 32.16 | 31.5 ± 24.18 |
The correlation of FVC (mL) between home and site spirometry was analyzed by taking into account the individually estimated linear regression models of each participant for home-based FVC measurements and site FVC measurements. This analysis was performed for participants diagnosed with IPF or non-IPF ILD in the peri-diagnosis period. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
| Pearson's Correlation Coefficients | IPF Participants | Non-IPF ILD Participants |
|---|---|---|
| Pearson's Correlation Coefficient of FVC (mL) Between Home and Site Spirometry in IPF and Non-IPF ILD Participants During the Peri-Diagnostic Period | -0.06 | 0.35 |
The measure represents the correlation of distance walked (meter) assessed by physical function capacity at home and the 6MWT at the site in the peri-diagnosis period. The peri-diagnostic period covered the pre-diagnostic period (from inclusion into the study (enrollment visit), participants were followed for a maximum of 12 months in the pre-diagnostic assessment period) and the post-diagnostic period (from diagnosis to the start of drug treatment within 6 months or a maximum of 6 months if no drug treatment was prescribed).
| Pearson's Correlation Coefficients | IPF Participants | Non-IPF ILD Participants |
|---|---|---|
| Pearson's Correlation Coefficient of Physical Functional Capacity Assessed at Home in Terms of the Decline in the Number of Footsteps and on Site in Terms of the Decline in Distance of the 6MWT | -0.04 | 0.06 |
The number of participants requiring the hospitalization were counted during pre- and post-diagnosis period.
| Percentage of Participants | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis |
|---|---|---|---|---|
| With at least one event during pre-diagnosis period | 5.9 | 4.8 | 22.2 | 2.6 |
| With at least one event during post-diagnosis period | 0 | 0 | 0 | 0 |
The number of participants requiring the hospitalization were counted during pre- and post-diagnosis period. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.
| Percentage of Participants | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis |
|---|---|---|---|---|
| With at least one event during pre-diagnosis period | 8.8 | 4.8 | 22.2 | 7.7 |
| With at least one event during post-diagnosis period | 2.9 | 0 | 0 | 0 |
Acute exacerbation was defined as per Collard et al. 2016. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.
| Percentage of Participants | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis |
|---|---|---|---|---|
| With at least one acute exacerbation pre-diagnosis period | 1.5 | 0 | 0 | 0 |
| With at least one acute exacerbation during post-diagnosis period | 0 | 0 | — | — |
| With at least one triggered acute exacerbation pre-diagnosis period | 4.4 | 0 | 0 | 0 |
| With at least one triggered acute exacerbation during post-diagnosis period | 0 | 0 | — | — |
| With at least one idiopathic acute exacerbation pre-diagnosis period | 0 | 1.6 | 0 | 0 |
| With at least one idiopathic acute exacerbation during post-diagnosis period | 0 | 0 | — | — |
The number of participants, who died due to any cause, were counted during pre- and post-diagnosis period.
| Percentage of Participants | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis |
|---|---|---|---|---|
| Percentage of Participants Who Died Due to Any Cause | 0 | 0 | 0 | 0 |
The number of participants, who died due to respiratory-related diseases, were counted during pre- and post-diagnosis period.
| Percentage of Participants | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis |
|---|---|---|---|---|
| Percentage of Participants Who Died Due to Respiratory-Related Diseases | 0 | 0 | 0 | 0 |
The number of participants with events related to the study assessments were counted during pre- and post-diagnosis period. Investigator-reported acute exacerbations, deaths, and events related to study assessments were only collected in the clinical database. As the study had no protocol mandated IMP or treatment requirements, any untoward occurrences such as AEs and SAEs were not collected.
| Percentage of Participants | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis |
|---|---|---|---|---|
| Percentage of Participants With Events Related to the Study Assessments | 0 | 3.2 | 0 | 5.1 |
Collected over From inclusion into the study to end of the study (up to 18 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IPF Participants | 0/68 (0%) | — | — |
| Participants With and an ILD Other Than IPF (Non-IPF ILD) | 0/62 (0%) | — | — |
| Non-ILD Participants | 0/9 (0%) | — | — |
| Participants Without Diagnosis | 0/39 (0%) | — | — |
| Age, Continuous(Years) | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis | Total |
|---|---|---|---|---|---|
| Mean | 69.3 ± 6.97 | 65.1 ± 9.99 | 69.6 ± 7.7 | 71.2 ± 8.64 | 68.3 ± 8.8 |
| Sex: Female, Male(Participants) | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis | Total |
|---|---|---|---|---|---|
| Female | 19 | 32 | 3 | 12 | 66 |
| Male | 49 | 30 | 6 | 27 | 112 |
| Race/Ethnicity, Customized(Participants) | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis | Total |
|---|---|---|---|---|---|
| American Indian or Alaskan Native | 1 | 0 | 0 | 0 | 1 |
| White | 62 | 50 | 7 | 24 | 143 |
| Unknown | 0 | 1 | 0 | 0 | 1 |
| Missing | 5 | 11 | 2 | 15 | 33 |
| Race/Ethnicity, Customized(Participant) | IPF Participants | Non-IPF ILD Participants | Non-ILD Participants | Participants Without Diagnosis | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 12 | 0 | 1 | 22 |
| Not Hispanic or Latin | 49 | 36 | 7 | 20 | 112 |
| Not reported | 4 | 3 | 0 | 2 | 9 |
| Unknown | 1 | 0 | 0 | 1 | 2 |
| Missing | 5 | 11 | 2 | 15 | 33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Dec 2017 to primary completion in Nov 2019, 23 months.
Results were first posted in Mar 2021, 1 year 3 months after primary completion.
Of 52 interventional studies with no phase under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 53. This study's 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idiopathic Pulmonary Fibrosis →